Medication 13: Everolimus (Afinitor) – An mTOR Inhibitor
Everolimus, sold under the brand name Afinitor, marks a departure from most thyroid cancer medications by acting as an mTOR inhibitor. mTOR is a protein that plays a crucial role in cell division and blood vessel growth. By inhibiting this protein, Everolimus helps control the growth and spread of thyroid cancer cells.
Everolimus works by blocking the action of mTOR, effectively disrupting the proliferation of cancer cells and the growth of new blood vessels. This unique action provides a new avenue for managing the progression of thyroid cancer.
Everolimus has shown promise in treating advanced thyroid cancer, particularly in patients where conventional treatments have failed. While it may not be the first line of treatment, Everolimus has its niche in managing this challenging disease.
Despite its potential benefits, Everolimus does come with possible side effects. These can range from mouth sores and infections to hyperglycemia and lung problems. It’s essential for patients to report any side effects to their healthcare provider for prompt and effective management.
In conclusion, Everolimus offers a crucial treatment option for patients with advanced thyroid cancer. Its unique action as an mTOR inhibitor provides an additional strategy to control the progression of this challenging disease. (13)
